Skip to main content
Top
Published in: Current Cardiology Reports 12/2016

01-12-2016 | Hypertension (AJ Peixoto and DS Geller, Section Editors)

Hypertension in Pregnancy: Defining Blood Pressure Goals and the Value of Biomarkers for Preeclampsia

Authors: Pitchaphon Nissaisorakarn, Sairah Sharif, Belinda Jim

Published in: Current Cardiology Reports | Issue 12/2016

Login to get access

Abstract

Hypertensive disorders in pregnancy have been the cause of much clinical dilemma, affecting up to 10 % of all pregnancies. The precise blood pressure to achieve in a pregnant woman is usually a battle between minimizing end organ damage to the mother and providing adequate perfusion to the placenta and the fetus. This predicament is becoming more, not less, frequent as maternal ages increase in high resource nations. Biomarkers to predict preeclampsia, a subcategory of hypertension in pregnancy, have always been elusive. The discovery of angiogenic factors relevant to preeclampsia in the last decade, however, has propelled much needed research, both in the basic science and clinical arenas. In this review, we summarize the latest clinical studies and international guidelines on blood pressure goals in pregnancy, and discuss the most promising of biomarkers to predict or diagnose preeclampsia.
Literature
1.
go back to reference ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99:159–67. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99:159–67.
2.
go back to reference von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355(9198):87–92.CrossRef von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355(9198):87–92.CrossRef
3.
go back to reference Pritchard JA, Pritchard SA. Standardized treatment of 154 consecutive cases of eclampsia. Am J Obstet Gynecol. 1975;123(5):543–52.CrossRefPubMed Pritchard JA, Pritchard SA. Standardized treatment of 154 consecutive cases of eclampsia. Am J Obstet Gynecol. 1975;123(5):543–52.CrossRefPubMed
4.
go back to reference Martin Jr JN, Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol. 2005;105(2):246–54.CrossRefPubMed Martin Jr JN, Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol. 2005;105(2):246–54.CrossRefPubMed
5.••
go back to reference Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(5):407–17. This was a large randomized control study that showed that tight control of blood pressure during pregnancy to a diastolic blood pressure of equal to or less than 85 mm Hg did not show worse maternal or fetal outcomes than less tight control of diastolic blood pressure to greater than 85 mmHg.CrossRefPubMed Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(5):407–17. This was a large randomized control study that showed that tight control of blood pressure during pregnancy to a diastolic blood pressure of equal to or less than 85 mm Hg did not show worse maternal or fetal outcomes than less tight control of diastolic blood pressure to greater than 85 mmHg.CrossRefPubMed
6.
go back to reference Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007;1:CD002252. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007;1:CD002252.
7.
go back to reference Chapman AB, Abraham WT, Zamudio S, Coffin C, Merouani A, Young D, et al. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int. 1998;54(6):2056–63.CrossRefPubMed Chapman AB, Abraham WT, Zamudio S, Coffin C, Merouani A, Young D, et al. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int. 1998;54(6):2056–63.CrossRefPubMed
8.••
go back to reference American College of O, Gynecologists, Task Force on Hypertension in P. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122–31. This was a updated set of guidelines by the American Society of Obstetricians and Gynecology mainly to denote a more inclusive definition of preeclampsia, that it can occur in the absence of proteinuria if there is new onset of hypertension after 20 weeks of gestation with new onset derangements in the liver/heart/lung/kidney function/cerebral function or symptoms, or platelet count.CrossRef American College of O, Gynecologists, Task Force on Hypertension in P. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122–31. This was a updated set of guidelines by the American Society of Obstetricians and Gynecology mainly to denote a more inclusive definition of preeclampsia, that it can occur in the absence of proteinuria if there is new onset of hypertension after 20 weeks of gestation with new onset derangements in the liver/heart/lung/kidney function/cerebral function or symptoms, or platelet count.CrossRef
9.
go back to reference S. A. Bowyer, L. Lust, K. McMahon, L. P. Morton, M. R. North, R. A. Paech, M. J.Said, J. M.The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014, Aust N Z J Obstet Gynaecol, 2015; 55:11–6. S. A. Bowyer, L. Lust, K. McMahon, L. P. Morton, M. R. North, R. A. Paech, M. J.Said, J. M.The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014, Aust N Z J Obstet Gynaecol, 2015; 55:11–6.
10.
go back to reference Kuklina EV, Tong X, Bansil P, George MG, Callaghan WM. Trends in pregnancy hospitalizations that included a stroke in the United States from 1994 to 2007: reasons for concern? Stroke. 2011;42(9):2564–70.CrossRefPubMed Kuklina EV, Tong X, Bansil P, George MG, Callaghan WM. Trends in pregnancy hospitalizations that included a stroke in the United States from 1994 to 2007: reasons for concern? Stroke. 2011;42(9):2564–70.CrossRefPubMed
11.
12.
go back to reference Esh Esc Task Force for the Management of Arterial Hypertension, 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension, J Hypertens, 2013; 31:1925–38. Esh Esc Task Force for the Management of Arterial Hypertension, 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension, J Hypertens, 2013; 31:1925–38.
13.
go back to reference Redman C. The six stages of pre-eclampsia. Pregnancy Hypertens. 2014; 4(3):246.PubMed Redman C. The six stages of pre-eclampsia. Pregnancy Hypertens. 2014; 4(3):246.PubMed
14.
go back to reference Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, Zeeman GG, Brown MA. The Classification, Diagnosis and Management of the Hypertensive Disorders of Pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014; 4:97–104. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, Zeeman GG, Brown MA. The Classification, Diagnosis and Management of the Hypertensive Disorders of Pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014; 4:97–104.
15.
go back to reference Kam EP, Gardner L, Loke YW, King A. The role of trophoblast in the physiological change in decidual spiral arteries. Hum Reprod. 1999;14(8):2131–8.CrossRefPubMed Kam EP, Gardner L, Loke YW, King A. The role of trophoblast in the physiological change in decidual spiral arteries. Hum Reprod. 1999;14(8):2131–8.CrossRefPubMed
16.
go back to reference Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005;46(5):1077–85.CrossRefPubMed Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005;46(5):1077–85.CrossRefPubMed
17.
go back to reference Saito S, Nakashima A. A review of the mechanism for poor placentation in early-onset preeclampsia: the role of autophagy in trophoblast invasion and vascular remodeling. J Reprod Immunol. 2014;101–102:80–8.CrossRefPubMed Saito S, Nakashima A. A review of the mechanism for poor placentation in early-onset preeclampsia: the role of autophagy in trophoblast invasion and vascular remodeling. J Reprod Immunol. 2014;101–102:80–8.CrossRefPubMed
18.
go back to reference Lyall F. Priming and remodelling of human placental bed spiral arteries during pregnancy--a review. Placenta. 2005;26(Suppl A):S31–6.CrossRefPubMed Lyall F. Priming and remodelling of human placental bed spiral arteries during pregnancy--a review. Placenta. 2005;26(Suppl A):S31–6.CrossRefPubMed
19.
20.
go back to reference Murphy SR, Cockrell K. Regulation of soluble fms-like tyrosine kinase-1 production in response to placental ischemia/hypoxia: role of angiotensin II. Physiol Rep. 2015;3:2.CrossRef Murphy SR, Cockrell K. Regulation of soluble fms-like tyrosine kinase-1 production in response to placental ischemia/hypoxia: role of angiotensin II. Physiol Rep. 2015;3:2.CrossRef
21.
go back to reference Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2008;294(2):H541–50.CrossRefPubMed Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2008;294(2):H541–50.CrossRefPubMed
22.
go back to reference McElrath TF1, Lim KH, Pare E, Rich-Edwards J, Pucci D, Troisi R, Parry S. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol. 2012 Nov;207(5):407.e1-7. doi:10.1016/j.ajog.2012.08.010 McElrath TF1, Lim KH, Pare E, Rich-Edwards J, Pucci D, Troisi R, Parry S. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol. 2012 Nov;207(5):407.e1-7. doi:10.​1016/​j.​ajog.​2012.​08.​010
23.
go back to reference Khalil A1, Cowans NJ, Spencer K, Goichman S, Meiri H, Harrington K. First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk. Prenat Diagn. 2009;29(8):781-9. doi:10.1002/pd.2287 Khalil A1, Cowans NJ, Spencer K, Goichman S, Meiri H, Harrington K. First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk. Prenat Diagn. 2009;29(8):781-9. doi:10.​1002/​pd.​2287
24.
go back to reference Schneuer FJ, Nassar N, Khambalia AZ, Tasevski V, Guilbert C, Ashton AW, Morris JM, Roberts CL. First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: in-house study and systematic review. Placenta 2012;33(9):735-40. doi:10.1016/j.placenta.2012.05.012. Review Schneuer FJ, Nassar N, Khambalia AZ, Tasevski V, Guilbert C, Ashton AW, Morris JM, Roberts CL. First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: in-house study and systematic review. Placenta 2012;33(9):735-40. doi:10.​1016/​j.​placenta.​2012.​05.​012. Review
25.
go back to reference Buhimschi IA, Nayeri UA, Zhao G, Shook LL, Pensalfini A, Funai EF, Bernstein IM, Glabe CG, Buhimschi CS. Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. Sci Transl Med. 2014 Jul 16;6(245):245ra92. Buhimschi IA, Nayeri UA, Zhao G, Shook LL, Pensalfini A, Funai EF, Bernstein IM, Glabe CG, Buhimschi CS. Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. Sci Transl Med. 2014 Jul 16;6(245):245ra92.
26.
go back to reference Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic Therapies. Genes Cancer. 2011;2(12):1097–105.CrossRefPubMedPubMedCentral Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic Therapies. Genes Cancer. 2011;2(12):1097–105.CrossRefPubMedPubMedCentral
27.•
go back to reference Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111(5):707–16. This study showed that the dosage of VEGF was important in determining whether mice developed features of preeclampsia or HIVAN.CrossRefPubMedPubMedCentral Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111(5):707–16. This study showed that the dosage of VEGF was important in determining whether mice developed features of preeclampsia or HIVAN.CrossRefPubMedPubMedCentral
28.••
go back to reference Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–58. This was the first animal study that showed the pathogenicity of sFlt-1 in causing clinical features of preeclampsia.CrossRefPubMedPubMedCentral Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–58. This was the first animal study that showed the pathogenicity of sFlt-1 in causing clinical features of preeclampsia.CrossRefPubMedPubMedCentral
30.
go back to reference Athanassiades A, Lala PK. Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness. Placenta. 1998;19(7):465–73.CrossRefPubMed Athanassiades A, Lala PK. Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness. Placenta. 1998;19(7):465–73.CrossRefPubMed
31.
go back to reference Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem. 1999;274(2):584–94.CrossRefPubMed Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem. 1999;274(2):584–94.CrossRefPubMed
32.
go back to reference Kapur NK, Morine KJ, Letarte M. Endoglin: a critical mediator of cardiovascular health. Vasc Health Risk Manage. 2013;9:195–206.CrossRef Kapur NK, Morine KJ, Letarte M. Endoglin: a critical mediator of cardiovascular health. Vasc Health Risk Manage. 2013;9:195–206.CrossRef
33.
go back to reference Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642–9.CrossRefPubMed Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642–9.CrossRefPubMed
34.
go back to reference Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res. 2005;65(3):599–608.CrossRefPubMed Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res. 2005;65(3):599–608.CrossRefPubMed
36.
go back to reference Rossi E, Smadja DM, Boscolo E, Langa C, Arevalo MA, Pericacho M, et al. Endoglin regulates mural cell adhesion in the circulatory system. CMLS. 2016;73(8):1715–39.CrossRefPubMed Rossi E, Smadja DM, Boscolo E, Langa C, Arevalo MA, Pericacho M, et al. Endoglin regulates mural cell adhesion in the circulatory system. CMLS. 2016;73(8):1715–39.CrossRefPubMed
34.•
go back to reference Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2008;93(1):260–6. This study showed that angiogenic markers predated the development of clinical preeclampsia in a case control study.CrossRefPubMed Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2008;93(1):260–6. This study showed that angiogenic markers predated the development of clinical preeclampsia in a case control study.CrossRefPubMed
38.
go back to reference Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992–1005.CrossRefPubMed Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992–1005.CrossRefPubMed
39.
go back to reference Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007;50(1):137–42.CrossRefPubMed Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007;50(1):137–42.CrossRefPubMed
40.
go back to reference Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem. 2004;50(9):1702–3.CrossRefPubMed Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem. 2004;50(9):1702–3.CrossRefPubMed
41.
go back to reference Myatt L, Clifton RG, Roberts JM, Spong CY, Wapner RJ, Thorp Jr JM, et al. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? BJOG. 2013;120(10):1183–91.CrossRefPubMedPubMedCentral Myatt L, Clifton RG, Roberts JM, Spong CY, Wapner RJ, Thorp Jr JM, et al. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? BJOG. 2013;120(10):1183–91.CrossRefPubMedPubMedCentral
42.
go back to reference Myers JE, Kenny LC, McCowan LM, Chan EH, Dekker GA, Poston L, et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG. 2013;120:1215–23.CrossRefPubMed Myers JE, Kenny LC, McCowan LM, Chan EH, Dekker GA, Poston L, et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG. 2013;120:1215–23.CrossRefPubMed
43.
go back to reference Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG. 2012;119(7):778–87.CrossRefPubMed Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG. 2012;119(7):778–87.CrossRefPubMed
44.
go back to reference De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'Anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand. 2008;87(8):837–42.CrossRefPubMed De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'Anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand. 2008;87(8):837–42.CrossRefPubMed
45.
go back to reference Liu Y, Zhao Y, Yu A, Zhao B, Gao Y, Niu H. Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Arch Gynecol Obstet. 2015;292(3):507–18.CrossRefPubMed Liu Y, Zhao Y, Yu A, Zhao B, Gao Y, Niu H. Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Arch Gynecol Obstet. 2015;292(3):507–18.CrossRefPubMed
46.
go back to reference Stepan H, Hund M, Gencay M, Denk B, Dinkel C, Kaminski WE, et al. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. Hypertens Pregnancy. 2016;30:1–11. Stepan H, Hund M, Gencay M, Denk B, Dinkel C, Kaminski WE, et al. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. Hypertens Pregnancy. 2016;30:1–11.
47.
go back to reference Fisher KA, Luger A, Spargo BH, Lindheimer MD. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine. 1981;60(4):267–76.CrossRefPubMed Fisher KA, Luger A, Spargo BH, Lindheimer MD. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine. 1981;60(4):267–76.CrossRefPubMed
48.
go back to reference Moore AG, Young H, Keller JM, Ojo LR, Yan J, Simas TA, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Maternal Fetal Neonatal Med. 2012;25(12):2651–7.CrossRef Moore AG, Young H, Keller JM, Ojo LR, Yan J, Simas TA, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Maternal Fetal Neonatal Med. 2012;25(12):2651–7.CrossRef
49.
go back to reference Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, Cerdeira AS, et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy. 2013;32(2):189–201.CrossRefPubMedPubMedCentral Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, Cerdeira AS, et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy. 2013;32(2):189–201.CrossRefPubMedPubMedCentral
50.
go back to reference Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected Preeclampsia. N Engl J Med. 2016;374(1):13–22.CrossRefPubMed Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected Preeclampsia. N Engl J Med. 2016;374(1):13–22.CrossRefPubMed
51.
go back to reference Garovic VD, Wagner SJ, Petrovic LM, Gray CE, Hall P, Sugimoto H, et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dialysis Transplant. 2007;22(4):1136–43.CrossRef Garovic VD, Wagner SJ, Petrovic LM, Gray CE, Hall P, Sugimoto H, et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dialysis Transplant. 2007;22(4):1136–43.CrossRef
52.
go back to reference Garovic VD, Wagner SJ, Turner ST, Rosenthal DW, Watson WJ, Brost BC, et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol. 2007;196(4):320 e1–7.CrossRef Garovic VD, Wagner SJ, Turner ST, Rosenthal DW, Watson WJ, Brost BC, et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol. 2007;196(4):320 e1–7.CrossRef
53.
go back to reference Jim B, Jean-Louis P, Qipo A, Garry D, Mian S, Matos T, et al. Podocyturia as a diagnostic marker for preeclampsia amongst high-risk pregnant patients. J Pregnancy. 2012;2012:984630.CrossRefPubMedPubMedCentral Jim B, Jean-Louis P, Qipo A, Garry D, Mian S, Matos T, et al. Podocyturia as a diagnostic marker for preeclampsia amongst high-risk pregnant patients. J Pregnancy. 2012;2012:984630.CrossRefPubMedPubMedCentral
54.
go back to reference Wang Y, Zhao S, Loyd S, Groome LJ. Increased urinary excretion of nephrin, podocalyxin, and betaig-h3 in women with preeclampsia. Am J Physiol Renal Physiol. 2012;302(9):F1084–9.CrossRefPubMed Wang Y, Zhao S, Loyd S, Groome LJ. Increased urinary excretion of nephrin, podocalyxin, and betaig-h3 in women with preeclampsia. Am J Physiol Renal Physiol. 2012;302(9):F1084–9.CrossRefPubMed
55.
go back to reference Aita K, Etoh M, Hamada H, Yokoyama C, Takahashi A, Suzuki T, et al. Acute and transient podocyte loss and proteinuria in preeclampsia. Nephron Clin Pract. 2009;112(2):c65–70.CrossRefPubMed Aita K, Etoh M, Hamada H, Yokoyama C, Takahashi A, Suzuki T, et al. Acute and transient podocyte loss and proteinuria in preeclampsia. Nephron Clin Pract. 2009;112(2):c65–70.CrossRefPubMed
56.
go back to reference Craici IM, Wagner SJ, Bailey KR, Fitz-Gibbon PD, Wood-Wentz CM, Turner ST, et al. Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study. Hypertension. 2013;61(6):1289–96.CrossRefPubMedPubMedCentral Craici IM, Wagner SJ, Bailey KR, Fitz-Gibbon PD, Wood-Wentz CM, Turner ST, et al. Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study. Hypertension. 2013;61(6):1289–96.CrossRefPubMedPubMedCentral
57.
go back to reference Jim B, Mehta S, Qipo A, Kim K, Cohen HW, Moore RM, et al. A comparison of podocyturia, albuminuria and nephrinuria in predicting the development of preeclampsia: a prospective study. PLoS One. 2014;9(7):e101445.CrossRefPubMedPubMedCentral Jim B, Mehta S, Qipo A, Kim K, Cohen HW, Moore RM, et al. A comparison of podocyturia, albuminuria and nephrinuria in predicting the development of preeclampsia: a prospective study. PLoS One. 2014;9(7):e101445.CrossRefPubMedPubMedCentral
58.
go back to reference Kelder TP, Penning ME, Uh HW, Cohen D, Bloemenkamp KW, Bruijn JA, et al. Quantitative polymerase chain reaction-based analysis of podocyturia is a feasible diagnostic tool in preeclampsia. Hypertension. 2012. Dec;60(6):1538–44 Kelder TP, Penning ME, Uh HW, Cohen D, Bloemenkamp KW, Bruijn JA, et al. Quantitative polymerase chain reaction-based analysis of podocyturia is a feasible diagnostic tool in preeclampsia. Hypertension. 2012. Dec;60(6):1538–44
59.
go back to reference Than NG, Pick E, Bellyei S, Szigeti A, Burger O, Berente Z, et al. Functional analyses of placental protein 13/galectin-13. Eur J Biochem/FEBS. 2004;271(6):1065–78.CrossRef Than NG, Pick E, Bellyei S, Szigeti A, Burger O, Berente Z, et al. Functional analyses of placental protein 13/galectin-13. Eur J Biochem/FEBS. 2004;271(6):1065–78.CrossRef
60.
go back to reference Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2007;197(1):35 e1–7.CrossRef Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2007;197(1):35 e1–7.CrossRef
61.
go back to reference Huppertz B, Sammar M, Chefetz I, Neumaier-Wagner P, Bartz C, Meiri H. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagnosis Ther. 2008;24(3):230–6.CrossRef Huppertz B, Sammar M, Chefetz I, Neumaier-Wagner P, Bartz C, Meiri H. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagnosis Ther. 2008;24(3):230–6.CrossRef
62.
go back to reference Romero R, Kusanovic JP, Than NG, Erez O, Gotsch F, Espinoza J, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol. 2008;199(2):122 e1–e11.CrossRef Romero R, Kusanovic JP, Than NG, Erez O, Gotsch F, Espinoza J, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol. 2008;199(2):122 e1–e11.CrossRef
63.
go back to reference Spencer K, Cowans NJ, Chefetz I, Tal J, Meiri H. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol. 2007;29(2):128–34.CrossRefPubMed Spencer K, Cowans NJ, Chefetz I, Tal J, Meiri H. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol. 2007;29(2):128–34.CrossRefPubMed
64.
go back to reference Stamatopoulou A, Cowans NJ, Matwejew E, von Kaisenberg C, Spencer K. Placental protein-13 and pregnancy-associated plasma protein-A as first trimester screening markers for hypertensive disorders and small for gestational age outcomes. Hypertens Pregnancy. 2011;30(4):384–95.CrossRefPubMed Stamatopoulou A, Cowans NJ, Matwejew E, von Kaisenberg C, Spencer K. Placental protein-13 and pregnancy-associated plasma protein-A as first trimester screening markers for hypertensive disorders and small for gestational age outcomes. Hypertens Pregnancy. 2011;30(4):384–95.CrossRefPubMed
65.
go back to reference Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenatal Diagn. 2009;29(12):1103–8.CrossRef Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenatal Diagn. 2009;29(12):1103–8.CrossRef
66.
go back to reference Seravalli V, Grimpel YI, Meiri H, Blitzer M, Baschat AA. Relationship between first-trimester serum placental protein-13 and maternal characteristics, placental Doppler studies and pregnancy outcome. J Perinatal Med. 2016. Jul 1;44(5):543–9 Seravalli V, Grimpel YI, Meiri H, Blitzer M, Baschat AA. Relationship between first-trimester serum placental protein-13 and maternal characteristics, placental Doppler studies and pregnancy outcome. J Perinatal Med. 2016. Jul 1;44(5):543–9
67.
go back to reference Wu P, van den Berg C, Alfirevic Z, O'Brien S, Rothlisberger M, Baker PN, et al. Early pregnancy biomarkers in preeclampsia: a systematic review and meta-analysis. Int J Mol Sci. 2015;16(9):23035–56. Wu P, van den Berg C, Alfirevic Z, O'Brien S, Rothlisberger M, Baker PN, et al. Early pregnancy biomarkers in preeclampsia: a systematic review and meta-analysis. Int J Mol Sci. 2015;16(9):23035–56.
68.
go back to reference Odibo AO, Goetzinger KR, Odibo L, Cahill AG, Macones GA, Nelson DM, et al. First-trimester prediction of preeclampsia using metabolomic biomarkers: a discovery phase study. Prenatal Diagn. 2011;31(10):990–4.CrossRef Odibo AO, Goetzinger KR, Odibo L, Cahill AG, Macones GA, Nelson DM, et al. First-trimester prediction of preeclampsia using metabolomic biomarkers: a discovery phase study. Prenatal Diagn. 2011;31(10):990–4.CrossRef
69.
go back to reference Folkersen J, Grudzinskas JG, Hindersson P, Teisner B, Westergaard JG. Pregnancy-associated plasma protein A: circulating levels during normal pregnancy. Am J Obstet Gynecol. 1981;139(8):910–4.CrossRefPubMed Folkersen J, Grudzinskas JG, Hindersson P, Teisner B, Westergaard JG. Pregnancy-associated plasma protein A: circulating levels during normal pregnancy. Am J Obstet Gynecol. 1981;139(8):910–4.CrossRefPubMed
71.
go back to reference Kalousova M, Muravska A, Zima T. Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia. Adv Clin Chem. 2014;63:169–209.CrossRefPubMed Kalousova M, Muravska A, Zima T. Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia. Adv Clin Chem. 2014;63:169–209.CrossRefPubMed
72.
go back to reference Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004;191(4):1446–51.CrossRefPubMed Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004;191(4):1446–51.CrossRefPubMed
73.
go back to reference Dane B, Dane C, Batmaz G, Ates S, Dansuk R. First trimester maternal serum pregnancy-associated plasma protein-A is a predictive factor for early preterm delivery in normotensive pregnancies. Gynecol Endocrinol. 2013;29(6):592–5.CrossRefPubMed Dane B, Dane C, Batmaz G, Ates S, Dansuk R. First trimester maternal serum pregnancy-associated plasma protein-A is a predictive factor for early preterm delivery in normotensive pregnancies. Gynecol Endocrinol. 2013;29(6):592–5.CrossRefPubMed
74.
go back to reference Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53(5):812–8.CrossRefPubMed Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53(5):812–8.CrossRefPubMed
75.
go back to reference Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002;87(4):1762–7.CrossRefPubMed Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002;87(4):1762–7.CrossRefPubMed
76.
go back to reference Anderson UD, Gram M, Akerstrom B, Hansson SR. First trimester prediction of preeclampsia. Curr Hypertens Reps. 2015;17(9):584. Anderson UD, Gram M, Akerstrom B, Hansson SR. First trimester prediction of preeclampsia. Curr Hypertens Reps. 2015;17(9):584.
77.
go back to reference McCarthy FP, Adetoba A, Gill C, Bramham K, Bertolaccini M, Burton GJ, et al. Urinary congophilia in women with hypertensive disorders of pregnancy and preexisting proteinuria or hypertension. Am J Obstet Gynecol. 2016. Oct;215(4):464.e1–7. McCarthy FP, Adetoba A, Gill C, Bramham K, Bertolaccini M, Burton GJ, et al. Urinary congophilia in women with hypertensive disorders of pregnancy and preexisting proteinuria or hypertension. Am J Obstet Gynecol. 2016. Oct;215(4):464.e1–7.
78.
go back to reference Argent NB, Burrell LM, Goodship TH, Wilkinson R, Baylis PH. Osmoregulation of thirst and vasopressin release in severe chronic renal failure. Kidney Int. 1991;39(2):295–300.CrossRefPubMed Argent NB, Burrell LM, Goodship TH, Wilkinson R, Baylis PH. Osmoregulation of thirst and vasopressin release in severe chronic renal failure. Kidney Int. 1991;39(2):295–300.CrossRefPubMed
79.
go back to reference Zulfikaroglu E, Islimye M, Tonguc EA, Payasli A, Isman F, Var T, et al. Circulating levels of copeptin, a novel biomarker in pre-eclampsia. J Obstet Gynaecol Res. 2011;37(9):1198–202.CrossRefPubMed Zulfikaroglu E, Islimye M, Tonguc EA, Payasli A, Isman F, Var T, et al. Circulating levels of copeptin, a novel biomarker in pre-eclampsia. J Obstet Gynaecol Res. 2011;37(9):1198–202.CrossRefPubMed
80.
go back to reference Foda AAAAI. Maternal and neonatal copeptin levels at cesarean section and vaginal delivery. Eur J Obstet Gynecol Reprod Biol. 2012;165(2):215–8.CrossRefPubMed Foda AAAAI. Maternal and neonatal copeptin levels at cesarean section and vaginal delivery. Eur J Obstet Gynecol Reprod Biol. 2012;165(2):215–8.CrossRefPubMed
81.
go back to reference Santillan MK, Santillan DA, Scroggins SM, Min JY, Sandgren JA, Pearson NA, et al. Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model. Hypertension. 2014;64(4):852–9.CrossRefPubMedPubMedCentral Santillan MK, Santillan DA, Scroggins SM, Min JY, Sandgren JA, Pearson NA, et al. Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model. Hypertension. 2014;64(4):852–9.CrossRefPubMedPubMedCentral
82.
go back to reference Papageorghiou AT, Leslie K. Uterine artery Doppler in the prediction of adverse pregnancy outcome. Curr Opin Obstet Gynecol. 2007;19(2):103–9.CrossRefPubMed Papageorghiou AT, Leslie K. Uterine artery Doppler in the prediction of adverse pregnancy outcome. Curr Opin Obstet Gynecol. 2007;19(2):103–9.CrossRefPubMed
83.
go back to reference Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Goncalves LF, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol. 2007;196(4):326 e1–13.CrossRef Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Goncalves LF, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol. 2007;196(4):326 e1–13.CrossRef
84.
go back to reference Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 2007;49(4):818–24.CrossRefPubMed Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 2007;49(4):818–24.CrossRefPubMed
85.
go back to reference Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ. 2008;178(6):701–11.CrossRefPubMedPubMedCentral Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ. 2008;178(6):701–11.CrossRefPubMedPubMedCentral
86.
go back to reference Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol. 2008;112(2 Pt 1):359–72.CrossRefPubMed Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol. 2008;112(2 Pt 1):359–72.CrossRefPubMed
87.
go back to reference Poon LC, Karagiannis G, Leal A, Romero XC, Nicolaides KH. Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11-13 weeks. Ultrasound Obstet Gynecol. 2009;34(5):497–502.CrossRefPubMed Poon LC, Karagiannis G, Leal A, Romero XC, Nicolaides KH. Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11-13 weeks. Ultrasound Obstet Gynecol. 2009;34(5):497–502.CrossRefPubMed
88.
go back to reference Odibo AO, Rada CC, Cahill AG, Goetzinger KR, Tuuli MG, Odibo L, et al. First-trimester serum soluble fms-like tyrosine kinase-1, free vascular endothelial growth factor, placental growth factor and uterine artery Doppler in preeclampsia. J Perinatol. 2013;33(9):670–4.CrossRefPubMed Odibo AO, Rada CC, Cahill AG, Goetzinger KR, Tuuli MG, Odibo L, et al. First-trimester serum soluble fms-like tyrosine kinase-1, free vascular endothelial growth factor, placental growth factor and uterine artery Doppler in preeclampsia. J Perinatol. 2013;33(9):670–4.CrossRefPubMed
89.
go back to reference Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenatal Diagn. 2011;31(1):66–74.CrossRef Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenatal Diagn. 2011;31(1):66–74.CrossRef
90.
go back to reference Giguere Y, Masse J, Theriault S, Bujold E, Lafond J, Rousseau F, et al. Screening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers. BJOG. 2015;122(3):402–10.CrossRefPubMed Giguere Y, Masse J, Theriault S, Bujold E, Lafond J, Rousseau F, et al. Screening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers. BJOG. 2015;122(3):402–10.CrossRefPubMed
91.
go back to reference Rasanen J, Girsen A, Lu X, Lapidus JA, Standley M, Reddy A, et al. Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia. J Proteome Res. 2010;9(8):4274–81.CrossRefPubMed Rasanen J, Girsen A, Lu X, Lapidus JA, Standley M, Reddy A, et al. Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia. J Proteome Res. 2010;9(8):4274–81.CrossRefPubMed
92.
go back to reference Carty DM, Siwy J, Brennand JE, Zurbig P, Mullen W, Franke J, et al. Urinary proteomics for prediction of preeclampsia. Hypertension. 2011;57(3):561–9.CrossRefPubMed Carty DM, Siwy J, Brennand JE, Zurbig P, Mullen W, Franke J, et al. Urinary proteomics for prediction of preeclampsia. Hypertension. 2011;57(3):561–9.CrossRefPubMed
93.
go back to reference Farina A, Zucchini C, Sekizawa A, Purwosunu Y, de Sanctis P, Santarsiero G, et al. Performance of messenger RNAs circulating in maternal blood in the prediction of preeclampsia at 10-14 weeks. Am J Obstet Gynecol. 2010;203(6):575 e1–7.CrossRef Farina A, Zucchini C, Sekizawa A, Purwosunu Y, de Sanctis P, Santarsiero G, et al. Performance of messenger RNAs circulating in maternal blood in the prediction of preeclampsia at 10-14 weeks. Am J Obstet Gynecol. 2010;203(6):575 e1–7.CrossRef
94.
go back to reference Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, McCowan L, et al. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension. 2010;56(4):741–9.CrossRefPubMed Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, McCowan L, et al. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension. 2010;56(4):741–9.CrossRefPubMed
95.
go back to reference Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, et al. First-trimester metabolomic detection of late-onset preeclampsia. Am J Obstet Gynecol. 2013;208(1):58 e1–7.CrossRef Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, et al. First-trimester metabolomic detection of late-onset preeclampsia. Am J Obstet Gynecol. 2013;208(1):58 e1–7.CrossRef
96.
go back to reference Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, et al. Metabolomics and first-trimester prediction of early-onset preeclampsia. J Maternal Fetal Neonatal Med. 2012;25(10):1840–7.CrossRef Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, et al. Metabolomics and first-trimester prediction of early-onset preeclampsia. J Maternal Fetal Neonatal Med. 2012;25(10):1840–7.CrossRef
97.
go back to reference Purwosunu Y, Sekizawa A, Farina A, Wibowo N, Okazaki S, Nakamura M, et al. Cell-free mRNA concentrations of CRH, PLAC1, and selectin-P are increased in the plasma of pregnant women with preeclampsia. Prenatal Diagn. 2007;27(8):772–7.CrossRef Purwosunu Y, Sekizawa A, Farina A, Wibowo N, Okazaki S, Nakamura M, et al. Cell-free mRNA concentrations of CRH, PLAC1, and selectin-P are increased in the plasma of pregnant women with preeclampsia. Prenatal Diagn. 2007;27(8):772–7.CrossRef
98.
go back to reference Levine RJ, Qian C, Leshane ES, Yu KF, England LJ, Schisterman EF, et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol. 2004;190(3):707–13.CrossRefPubMed Levine RJ, Qian C, Leshane ES, Yu KF, England LJ, Schisterman EF, et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol. 2004;190(3):707–13.CrossRefPubMed
99.
go back to reference Crowley A, Martin C, Fitzpatrick P, Sheils O, O'Herlihy C, O'Leary JJ, et al. Free fetal DNA is not increased before 20 weeks in intrauterine growth restriction or pre-eclampsia. Prenatal Diagn. 2007;27(2):174–9.CrossRef Crowley A, Martin C, Fitzpatrick P, Sheils O, O'Herlihy C, O'Leary JJ, et al. Free fetal DNA is not increased before 20 weeks in intrauterine growth restriction or pre-eclampsia. Prenatal Diagn. 2007;27(2):174–9.CrossRef
100.
go back to reference Sandrim VC, Luizon MR, Palei AC, Tanus-Santos JE, Cavalli RC. Circulating microRNA expression profiles in pre-eclampsia: evidence of increased miR-885-5p levels. BJOG. 2016. Feb 8. doi: 10.1111/1471-0528.13903. Sandrim VC, Luizon MR, Palei AC, Tanus-Santos JE, Cavalli RC. Circulating microRNA expression profiles in pre-eclampsia: evidence of increased miR-885-5p levels. BJOG. 2016. Feb 8. doi: 10.1111/1471-0528.13903.
101.
go back to reference Mitchell MD, Peiris HN, Kobayashi M, Koh YQ, Duncombe G, Illanes SE, et al. Placental exosomes in normal and complicated pregnancy. Am J Obstet Gynecol. 2015;213(4 Suppl):S173–81.CrossRefPubMed Mitchell MD, Peiris HN, Kobayashi M, Koh YQ, Duncombe G, Illanes SE, et al. Placental exosomes in normal and complicated pregnancy. Am J Obstet Gynecol. 2015;213(4 Suppl):S173–81.CrossRefPubMed
102.
go back to reference Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Canadian Hypertensive Disorders of Pregnancy (HDP)Working Group: Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens 2014; 4:105–145. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Canadian Hypertensive Disorders of Pregnancy (HDP)Working Group: Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens 2014; 4:105–145.
Metadata
Title
Hypertension in Pregnancy: Defining Blood Pressure Goals and the Value of Biomarkers for Preeclampsia
Authors
Pitchaphon Nissaisorakarn
Sairah Sharif
Belinda Jim
Publication date
01-12-2016
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 12/2016
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-016-0782-1

Other articles of this Issue 12/2016

Current Cardiology Reports 12/2016 Go to the issue

Psychological Aspects of Cardiovascular Diseases (A Steptoe, Section Editor)

Psychological Aspects of Heart Failure